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ABSTRACT
Aims: To demonstrate the efficacy of several small molecular weight compounds having hydrazide
groups, for inhibiting the growth of Mycobacterium tuberculosis. To show these same compounds
have favorable drug-likeness properties.
Study Design: To synthesize tuberculostats and test their antibacterial activity in-vitro.
Place and Duration of Study: University of Nebraska, Durham Science Center, 6001 Dodge
Street, Omaha NE 68182, and Texas A&M Health Science Center, Department of Microbial
Pathogenesis and Immunology, 8447 State Hwy 47, Medical Research and Education Building,
Room #3012, Bryan, TX 7780. From January 2015 to June 2015.
Methodology: Hydrazide groups were formed by covalently bonding hydrazine onto small
molecules having a single aromatic ring by utilizing microwave excitation and evaluating for
antibacterial activity. These compounds were placed into tissue culture media at various
_____________________________________________________________________________________________________
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concentrations and then tuberculosis bacteria were added to determine the level of growth
inhibition. Growth inhibition of the bacteria was measured as a function of compound concentration
for assessment and comparison.
Results: Compounds A, B, C, and D carry hydrazide groups with various substituents that are
bonded to a single aromatic ring. All four compounds show zero violations of Rule of 5, indicating
favorable absorption and membrane permeation. All four compounds showed greater than 85%
growth inhibition of bacteria at concentrations below 50 micrograms per milliliter, while assayed by
colony forming units and luminescence. Values of Log BB suggests compounds A and C will have
greater penetration into the central nervous system than isoniazid.
Conclusion: These four hydrazide compounds induced substantial inhibition of bacterial growth.
Microwave excitation for the synthesis of hydrazide compounds is effective. These compounds
have favorable drug-likeness properties and are highly effective inhibiting growth of Mycobacterium
tuberculosis.

Keywords: Tuberculosis; TB; hydrazide; Mycobacterium tuberculosis; tuberculostatic.
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Term: TB, tuberculosis; A , Angstroms ; A , Angstroms ; SMILES, simplified molecular-input line-entry
system; IUPAC, International Union of Pure and Applied Chemistry; MDR-TB, multi-drug resistant
Mycobacterium tuberculosis; M/XDR-TB, extensively drug resistant Mycobacterium tuberculosis;
TDR-TB, totally drug resistant tuberculosis; GPCR, G-protein-coupled receptors; CFU, colony forming
units; CNS, central nervous system.
Treatment for M. tuberculosis meningitis includes
isoniazid,
rifampicin,
pyrazinamide
and
ethambutol for a period of two months, which is
then followed by isoniazid and rifampicin alone
for a further ten months [5]. Interestingly, the
administration of aspirin may actually reduce or
even delay mortality [6]. TB meningitis is known
to occur more frequently in children and
especially children less than one year of age [7].

1. INTRODUCTION
Multi-drug resistant Mycobacterium tuberculosis
(MDR-TB) and extensively drug resistant
Mycobacterium tuberculosis (M/XDR-TB) is a
substantial challenge for clinicians and
public health workers worldwide [1]. The lack
of new effective drugs, improper regimens,
and unreliable drug susceptibility testing is
believed to have added to the problem [1].
MDR-TB patients having localized disease,
may benefit from utilization of surgery as an
adjunct to chemotherapy [1]. Summation in 2005,
indicated that an estimated 8.8 million new
cases of active tuberculosis were reported and
leading to an estimated 1.6 million deaths per
year [2].

Totally drug-resistant tuberculosis (TDR-TB) has
been reported in Iran, India and South Africa [8].
TDR-TB is most commonly described as an
incidence that is resistance to all first- line drugs
(isoniazid, rifampicin, pyrazinamide, ethambutol,
and streptomycin) and second-line drugs
administered to treat TB [8]. Adjunct TB
therapies, including repurposing of drugs that
target biologically molecular pathways, may
achieve better clinical outcomes in combination
with the standard chemotherapy [8]. Having
general symptomatic signs of fever, chills, night
sweats, appetite loss, and fatigue, cases of
pulmonary tuberculosis may infect any part of the
body where it is considered to be extrapulmonary
TB which may coexist with pulmonary TB as well
[9,10].

Tuberculosis (TB) infections of the central
nervous system (CNS) accounts for about 1%
of all cases of tuberculosis and carries a
high mortality level as well as causing
neurological
morbidity [2,3].
Tuberculosis
infection of the CNS is a devastating clinical
manifestations of tuberculosis. Often described
as meningitis, encephalitis is within the spectrum
of clinical manifestations [4]. In a previously
conducted
epidemiological
study
of
extrapulmonary tuberculosis within the United
States, involvement of the CNS was noted in 5
to 10% of all extrapulmonary tuberculosis
cases [2].

A latent tuberculosis infection is defined in a
patient that is infected with Mycobacterium
tuberculosis but has no active tuberculosis [11].
Although latent tuberculosis is not considered
2
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contagious, approximately 10% of these patients
will go on to develop active tuberculosis [11].
Identification and treatment of individuals having
latent TB is an important aspect of controlling the
disease, however treatment regimens generally
need to be administered for several months [11].

were determined by package GaussianGaussView 5.0 (Gaussian Inc., 340 Quinnipiac
St. Bldg. 40, Wallingford CT 06492 USA).

2.3 Bacterial Culture
2.3.1 Strain of bacteria

Clearly, new drug designs continuing studies are
well advised in the face of the threat of MDR-TB,
M/XDR-TB, and TDR-TB. This study presents
novel drug designs which apply the hydrazide
group found in the first-line drug isoniazid, to an
aromatic ring scaffolding that will modify
molecular
properties
favorably
for
oral
administration and penetration into the CNS.
This approach, to beneficially modify molecular
properties, has been shown to be highly
efficacious for inhibiting M. tuberculosis [12-15],
Staphylococcus aureus [16-18], and Escherichia
coli [19-22]. The novel hydrazide compounds
presented here are shown to significantly inhibit
the growth of M. tuberculosis and favorable druglikeness.

Mycobacterium tuberculosis strain CDC1551 wild
type carrying vector plasmid pJDC174 and BCG
carrying the same vector expressing a codonoptimized click beetle red gene (CBR) was used.
The bacteria were grown to an optical density
(OD) ~ 1.0 and then diluted to OD = 0.5 in media
for following survival assays (read at 600 nm
wavelength).
2.3.2 Media for In vitro evaluation of bacterial
growth inhibition
M. tuberculosis were grown in Middlebrook 7H9
supplemented with albumin dextrose complex
(M-ADC, per liter, 50 grams bovine serum
albumen fraction V, 20 grams dextrose, 8.5
grams NaCl, ) (Difco), 0.05% Tween 80 (M-ADCTw) and kanamycin at a final concentration of
10 µg/ml to select for plasmid maintenance in the
strains.

This study presents the efficacy of several small
hydrazide compounds for inhibiting the growth of
Mycobacterium tuberculosis. These same
compounds have favorable drug-likeness
properties.

2.3.3 In vitro evaluation of compounds

2. METHODOLOGY

All compounds were dissolved to a final
concentration of 5 mg/ml in aqueous solution. All
compound solutions were sterilized by passage
through 0.22 µm-syringe filters. Survival by
Optical Density: Four clear 96-well flat bottom
plates were filled with 108 µl per well of M-ADCTw media supplemented with 10 µg/ml
kanamycin to maintain luminescence in the
strain. Each tested compound, as well as
isoniazid, was added in duplicate wells at 72 µl
per well at a final concentration of 2 mg/ml. Twofold serial dilutions were carried out six times for
all compounds and isoniazid. The last row of
wells was maintained without any antibiotic. A 10
µl per well of M. tuberculosis (bacteria at equal
concentration in 10 µL for all wells) was added to
96-well plates to give a final volume of 100 µl per
well. Plates were incubated at 37°C for 3 days, 7
days and 14 days.

2.1 Reagents and Instrumentation
All reagents were obtained from Aldrich-Sigma
Company (P.O. Box 2060, Milwaukee, WI 53201
USA).
Infrared
spectroscopy
can
be
accomplished in a Mattson Galaxy FTIR in a
dimethyl sulfoxide solvent that has been
previously dried over molecular sieves to remove
water prior to obtaining spectra.

2.2 Molecular Modeling and Numerical
Analysis
Molecular modeling (2-D and 3-D) were
accomplished by ChemSketch version 12.01
ACD/Labs Release: 12.00 (90 Adelaide Street
West, Toronto, Ontario M5H 3V9, Canada)
Molecular properties were determined by utilizing
Molinspiration (Liscie Udolie 2, SK-841 04
Bratislava, Slovak Republic). Correlation statistic
by Pearson r and other statistical analysis was
accomplished by Microsoft Office Excel 2007 or
PAST version 2.06 (copyright Hammer and
Harper 1999-2011). Molecular dipole values

2.3.4 Measurement
luminescence

of

survival

by

Four solid white 96-well flat bottom plates were
prepared as before. Plates were incubated at
37°C for 3, 7, and 14 days. Luminescence
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measurements were taken for day 0, 3, 7, and
14 in the presence of tested compounds
[23]. Bacterial luminescence was measured
measured immediately after addition of 20 µl
of 5 mM D-luciferin in 0.45 M sodium
citrate buffer pH 5.0 (Gold Biotechnology)
using an EnVision (Perkin Elmer) plate
reader. Photon collection time was one second
per well.

3. RESULTS AND DISCUSSION
The investigation and development of novel
drugs for the treatment of Mycobacterium
tuberculosis infection is of pressing importance.
The appearance of multi-drug resistant and
extensively
drug-resistant
types
of
Mycobacterium tuberculosis will be a substantial
problem for clinical intervention. Four hydrazide
compounds have been synthesized utilizing
microwave excitation, followed by property
characterization, then in-vitro testing for bacterial
growth inhibition.

2.4 Synthesis of Compounds
Prior to use, the hydrazine (NH2NH2) must be
distilled over CaO and NaOH. The anhydrous
NH2NH2 was collected at 113°C and was stored
sealed at -20ºC. Hydrazide derivatization: All
compounds were treated similarly, place 120 mg
of compound into pyrex open test tube with 64
microliter of SOCl2. Microwave 3 to 5 minutes
(avoid over-heating as that will cause
degradation of the agent), allowed to cool
to room temperature. Vacuum pump removal
of
any
unreacted
thionyl
chloride
is
recommended. Add 400 microliter of anhydrous
NH2NH2 and microwave at 45 second intervals
up to five minutes (avoid excess heating
during process). Excess hydrazine was
removed by pump vacuum at room temperature.
The derivatives were not heated or allowed
to become wet. After thorough drying they
are stored dried in air tight containers at
-20°C. The presence of the hydrazine group can
be confirmed by use of FTIR, observing
for peaks at 944 cm-1 for hydrazine and 1000
cm-1 to 1200 cm-1 for C-N stretch, and
around 3000 cm-1 to 3500 cm-1 for N-H
stretch. Furthermore, the presence of the
hydrazide group on all final products can
be confirmed by the colorimetric protocol
and UV-Visible spectrophotometric analysis
utilizing Gibb’s reagent as described previously
[24]. Assignments of C-13 peaks for compounds
A, B, C, and D (ppm): (A) Aromatic carbons
C-1 133.4, C-2 128.0, C-3 137.8, C-4 132.6,
C-5 128.5, C-6 124.3, 3-methyl carbon 20.9,
carbonyl carbon 167.3; (B) Aromatic carbons C-1
133.9, C-2 120.2, C-3 153.2, C-4 124.8, C-5
129.0, C-6 124.1; carbonyl carbon 167.3;
carbonyl carbon 168.0 and methyl carbon 16.9;
(C) Aromatic carbons C-1 133.5, C-2 127.5, C-3
128.9, C-4 141.2, C-5 128.9, C-6 127.5; carbonyl
carbon 167.3; methylene bridge carbon 50.5; (D)
Aromatic carbons C-1 139.6, C-2 128.2, C-3
123.7, C-4 151.8, C-5 123.7, C-6 128.2; carbonyl
carbon 167.3.

These four compounds, A, B, C, and D are
presented for comparison in Fig. 1, with
molecular structure, IUPAC name, SMILES
(simplified molecular-input line-entry system
notation), and formula weight. Notably, each
compound has a single aromatic ring with a
hydrazide substituent (-C(O)NHNH2). The range
of formula weights runs from 150.18 (compound
A) to 194.19 (compound B). The hydrazide group
is common to all these compounds, as well as to
isoniazid (isonicotinylhydrazide), which is an
antibacterial used as a first-line agent in the
prevention and treatment of both latent and
active Mycobacterium tuberculosis infections
[1,8,9]. For compound A there is a methyl group
(-CH3) in meta position to the hydrazide group.
For compound B there is a –OC(O)CH3 group in
meta position to the hydrazide group. For
compound C there is a –CH2Cl group in para
position to the hydrazide group. Lastly,
compound D has a nitro group –NO2 in para
position to the hydrazide functional group. The
substituents of the aromatic ring plays an
important role in defining molecular properties of
each compound, which in turn defines the
efficacy of the compound for clinical application.
Various important properties such as Log P,
polar surface area, number of oxygen atoms,
number of nitrogen atoms, number of amine
groups (-NHn), and molecular volume have been
determined for each compound, and presented in
Table 1. One-way ANOVA test of all properties
for all compounds shown in Table 1 indicate that
the means of summed numerical values are
essentially equal (P = .99) [24]. Also, summed
properties of all compounds have equal medians
by Kruskal-WalIis test (P = .93) [24]. In addition,
the correlations of each compound’s properties
to another are extremely high, with Pearson r
greater than 0.9700 for all compounds and with
all properties inclusive (see Table 1).
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Angstroms2,
137.43
to
194.19,
122.56
3
3
Angstroms to 171.25 Angstroms , respectively.

O
NH

Compound A

NH2

3-methylbenzohydrazide

Notably, all compounds shown in Table 1 show
zero violations of the Rule of 5, which indicates
favorable drug absorption and permeation [26].
Previous studies have determined that poor
absorption of drug can occur when there are one
or more violations of the following parameters,
known as Rule of 5 [26]: 1) Molecular weight less
than 500; 2) Log P is less than 5; 3) There is no
more than 10 hydrogen bond acceptors (nitrogen
and oxygen atoms); 4) There is no more than 5
hydrogen bond donors (-OH & -NHn). Outcomes
for these compounds indicate an opportune
absorption into the body and efficient membrane
permeation predicted for compounds A, B, C,
and D. Oxygen and Nitrogen centered polar
fragments are considered in determination of
polar surface area and have been shown to be
good descriptors for characterizing drug
absorption, including intestinal absorption,
bioavailability, Caco-2 permeability and bloodbrain barrier penetration [26].

Cc1cccc(c1)C(=O)NN
CH3

Formula Weight

O

NH2

= 150.18

Compound B

NH

3-(hydrazinylcarbonyl)phenyl acetate
O=C(C)Oc1cc(ccc1)C(=O)NN
CH3

Formula Weight

= 194.19

O
O

O
NH

NH2

Compound C
4-(chloromethyl)benzohydrazide

Cl

ClCc1ccc(cc1)C(=O)NN
Formula Weight

= 184.62

O
NH
-

O

+

N

O

NH2

Number of rotatable bonds is a simple
topological parameter considered to be a
measure of molecular flexibility [26]. Previous
studies have shown the descriptor of BB
(Concentration in the brain/Concentration in
blood) can be accurately estimated and utilized
to determine if any perspective drug can be
expected to penetrate into the central nervous
system (CNS) [27,28]. Studies of drugs known to
efficiently pierce into the CNS have revealed an
equation for effectively predicting extent of drug
penetration, with that equation (1) presented
below [29]:

Compound D
4-nitrobenzohydrazide
O=[N+]([O-])c1ccc(cc1)C(=O)NN
Formula Weight

= 181.15

Fig. 1. Molecular structures, IUPAC names of
compounds, SMILES notation, and formula
weight of compounds A, B, C, and D. Note
that each compound has one aromatic ring
one hydrazide group (-C(=O)NHNH2).
Compound A has a methyl group (-CH3) in the
meta position to the hydrazide group. For
compound B the substituent (-O-C(=O)CH3) is
in the meta position to the hydrazide group.
However, for compound C the substituent
(-CH2Cl) is in the para position to the
hydrazide group; as is (-NO2) for compound D

Log BB = -0.0148(PSA) + 0.152(Log P) + 0.139
(1)
Applying equation (1) to PSA and Log P values
for compounds A, B, C, D, and isoniazid resulted
in the Log BB (from which BB is determined)
values for each, are presented in Table 2.
Interestingly, the BB value (Concentration in
brain/Concentration in blood) is 0.0966 for firstline tuberculostat isoniazid, whereas for
compounds A, B, and C are higher at 0.273,
0.0977, and 0.288, respectively. Essentially,
compounds A and C are predicted to have
significantly greater penetration into the central
nervous system for treatment of bacterial
infection due to Mycobacterium tuberculosis.
This is a very efficacious result, supporting the
positive potential of these compounds, as well as

Molecular properties of compounds A, B, C, D,
and isoniazid are presented in Table 1.
Searching for any outliers in numerical values
utilizing extreme studentized deviate (Grubbs’
test) [25], results showed no outliers in values of
Log P, polar surface area, molecular weight,
molecular volume, number of oxygen atoms,
number of nitrogen atoms, and number of
rotatable bonds. Ranges in numerical values for
important descriptors such as Log P, polar
surface area, molecular weight, and molecular
volume, inclusive of isoniazid, are as follows: 2
0.969, to 0.896; 55.12 Angstroms to 100.95
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property of chemicals which is widely integrated
into the early stages of lead and drug discovery
[32]. Methods that estimate drug-likeness are
valuable in the early stages of lead discovery,
and can be used to filter out compounds with
undesirable properties from screened libraries of
candidates and to prioritize candidates from
primary screens [32]. The goal is the
development of orally available drugs but these
approaches are also useful to optimize drug-like
pharmacokinetic properties [32]. Optimal ranges
for each drug category are indicated in the first
column labeled Category.

the study of structure modification that enhances
the absorption/permeation of tuberculostats.
Note that compound A has a methyl group
substituent, compound C has a –CH2Cl
substituent on the aromatic ring (see Fig. 1).
Small molecules have a greater chance to
penetrate into the central nervous system [27],
and molecules having a molecular weight less
than 400 have greater penetration [28].
Tuberculous meningitis is associated with high
morbidity and mortality with incidence of CNS
tuberculosis directly proportional to the
prevalence of tuberculous infection in general
[30].

Note that compounds A, B, C, and D all show
bioactivity scores falling within the optimal ranges
for drug categories GPCR ligand, ion channel
modulator, kinase inhibitor, protease inhibitor,
and enzyme inhibitor. Only in the category of
nuclear receptor ligand that compounds A and C
fall slightly outside the optimal range, while
compounds B and D fall within the optimal range.
This approach is known to provide useful
evaluation of the drug structure as to whether
there is consistency in scaffolding and similarity
to related clinical drugs.

Bioactivity scores for compounds A, B, C, and D
also indicate that these molecular scaffolds have
structures similar to optimal drug-likeness in six
major categories defined in Table 3. This
strategy leads to drug-likeness score, with focus
on particular drug classes and development of
specific activity score for each of these classes.
Drug-likeness scores assist in determining which
drug should be synthesized and screened [31].
Drug-likeness is often considered a qualitative

Table 1. Comparison of properties (Isoniazid and compounds A, B, C, and D)
Property

Isoniazid
-0.969
68.01

Compound
A
0.745
55.12

Compound
B
0.372
81.43

Compound
C
0.896
55.12

Compound
D
0.279
100.95

Log P
Polar Surface Area
2
(Angstroms )
Number of Atoms
Molecular Weight
Number of Oxygen Atoms
Number of Nitrogen Atoms
Number of -OH & -NHn
Number Rotatable Bonds
Molecular Volume
3
(Angstroms )
Violations Rule of 5
Dipole
(Debye)

10
137.43
1
3
2
1
122.56

11
150.18
1
2
2
1
143.28

14
194.19
3
2
2
3
171.25

12
184.63
1
2
2
2
157.06

13
181.15
3
3
2
2
150.05

0
4.835

0
4.947

0
2.522

0
5.614

0
3.481

Table 2. Penetration into central nervous system based on Log BB
Compound
A
B
C
D
Isoniazid

Log BB
-0.563
-1.01
-0.541
-1.31
-1.02

6

BB = Cbrain/Cblood
0.273
0.0977
0.288
0.0487
0.0966
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The scores for compounds A, B, C, and
D indicate favorable drug-likeness within
the
six
categories
examined.
These
favorable outcomes show these four compounds
to have potential for successful drug
candidates.

tuberculostat isoniazid, for comparison to novel
compounds.
Results that are presented in Fig. 2, show clearly
that all four novel compounds A, B, C, D, as well
as isoniazid very strongly inhibit the growth of
bacteria (more than 85%) at concentrations less
than 50 micrograms per milliliter. Near complete
bacterial inhibition is accomplished at all
concentrations greater than 100 micrograms per
milliliter. These results were observed at day 3
and day 14 (see Fig. 2).

Compounds A, B, C, and D were placed
into tissue culture at various concentrations,
then subjected to bacterial presence to
determine their effects on bacterial growth.
Similarly, this was accomplished with first-line

Table 3. Bioactivity scores of compounds
Category (Range)
GPCR ligand
(-1.50 to 0.50)
Ion channel modulator
(-2.00 to 0.50)
Kinase inhibitor
(-2.00 to 0.5)
Nuclear receptor ligand
(-2.00 to 0.50)
Protease inhibitor
(-2.00 to 0.50)
Enzyme inhibitor
(-1.50 to 0.50)

Compound A
-1.40

Compound B
-1.04

Compound C
-1.41

Compound D
-1.31

-1.59

-1.13

-1.43

-1.22

-1.29

-1.02

-1.49

-1.16

-2.04

-1.24

-2.23

-1.76

-1.25

-0.83

-0.84

-1.15

-0.84

-0.48

-0.66

-0.73

Fig. 2. Inhibition of bacterial growth induced by compounds A, B, C, and D; compared to
isoniazid at day 3 and day 14. Bacterial presence measured by luminescence. There is very
substantial inhibition of growth at concentrations less than 100 micrograms per milliliter.
Essentially complete inhibition occurs at higher concentrations

7
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Therefore, it can be concluded that the
suppression of bacteria occurs soon after
administration and follows strongly and
effectively for time period reaching from day 3 of
administration to day 14 (two weeks after).
Following bacterial inhibition by luminescence
provides accurate information to the extent of
microbial suppression and conveys a measure of
the bacterial metabolic activity, that in turn,
suggests that compounds A, B, C, and D rapidly
shuts down metabolism preceding bacterial
death.

milliliter. This very strong growth suppression is
sustained at concentrations greater than 100
micrograms per milliliter. Inhibition of growth as
measured by colony-forming units is very strong
and apparent soon after exposure at day 3 and
extends to day 14 (two week time period). These
results show clearly the very strong inhibitory
effect of compounds A, B, C, and D on the
growth of this deadly bacteria.
The design of new drugs for use in the ongoing
battle against the deadly infections of
Mycobacterium tuberculosis is a very necessary
endeavor. The appearance of multiple drug
resistant, extensively drug resistant, and totally
drug resistant bacterial types is a very strong
concern. Numerous nations are particularly
prone to have problems of containment due to
poor communication,
poor transportation,
poor economy, and lower quality of medical
support.

Similarly, when measured by colony-forming unit
(unit to estimate the number of viable bacteria)
all four compounds A, B, C, and D substantially
reduces bacteria survival (see Fig. 3). The level
of bacterial inhibition is similar to that induced by
first-line
tuberculostat
isoniazid.
Bacterial
inhibition greater than 85% is accomplished at
concentrations less than 50 micrograms per

Fig. 3. Inhibition of bacterial growth induced by compounds A, B, C, and D; compared to
isoniazid. Bacterial inhibition measured by colony-forming units (CFU). There is substantial
inhibition of growth at concentrations less than 100 micrograms per milliliter. Essentially
complete inhibition occurs at higher concentrations

8
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The development of new drugs will assist in
containment of bacterial outbreaks and
proliferation. The compounds presented in this
study are shown to substantially suppress
bacterial proliferation and possess properties
highly favorable in drug-likeness, absorption, and
bacterial inhibition.
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